New York, USA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Worldwide Cancer Monoclonal Antibodies Market size in 2021 was USD 51.88 billion and will be worth USD 108.47 billion with an 8.54% CAGR. A molecule created in a lab and designed to imitate the immune system's attack on cancer cells is known as a cancer monoclonal antibody. It can deliver radiation therapy directly to cancer cells, neutralizing or killing them. Chimeric, murine, and humanized monoclonal antibodies are among the most frequently used immunotherapies for brain, blood, liver, and breast cancer.
Make a Direct Purchase of the latest Cancer Monoclonal Antibodies Market Report published in the month of Jul-2022. Click the below link to initiate the purchase:
https://www.strategicmarketresearch.com/buy-now/cancer-monoclonal-antibodies-market
Cancer Monoclonal Antibodies Market Insights:
- With a share of over 39.5%, the market was ruled by humanized segment in 2021 on the basis of type.
- On the basis of application, blood cancer segment in 2021 was the biggest market, with a share of 23.3%.
- In the year 2021, the hospital segment held a considerable position in the market, with a share of 39.7% by end-user.
- North America in 2021 contributed for the highest market share of nearly 37.5%.
Factors influencing the Cancer Monoclonal Antibodies Market growth:
Factors like the rising cancer cases and widespread use of biosimilar antibodies are supporting the overall growth rate.
- A key factor stimulating market growth is the rising incidence of cancer worldwide. Monoclonal antibodies can treat inflammatory and autoimmune diseases and have less side effects on the patient's body than conventional non-targeted therapies like chemotherapy.
- The widespread use of affordable biosimilar monoclonal antibodies by healthcare professionals and oncologists is also boosting the market's expansion. They are equally effective but cost less than the original medication, which helps to improve the expense of the therapy and contributes to the rising demand for the product globally.
Cancer Monoclonal Antibodies Market: A thorough Segmentation Analysis
The Cancer Monoclonal Antibodies Market segmentation is based on Medication Type, Antibody Type, Application, end-user, and Region.
By Medication Type
- Trastuzumab (Herceptin)
- Pertuzumab (Perjeta)
- Bevacizumab (Avastin)
- Rituximab (Mabthera)
- Panitumumab (Vectibix)
- Cetuximab (Erbitux)
- Others
By End-User
- Research Laboratories
- Pharmacies
- Hospitals and Clinics
- Others
By Antibody Type
- Humanized Antibodies
- Chimeric Antibodies
- Murine Antibodies
- Others
By Application
- Brain Cancer
- Liver Cancer
- Breast Cancer
- Blood Cancer
- Colorectal Cancer
- Others
For Region
North America
- Canada
- USA
- Mexico
- Rest of North America
Asia-Pacific
- Australia
- Japan
- India
- China
- Rest of APAC
Europe
- Italy
- Spain
- U.K.
- Germany
- France
- The rest of Europe
LAMEA
- Saudi Arabia
- Brazil
- South Africa
- Rest of LAMEA
To get a first-hand overview of the report, Request a Sample at
https://www.strategicmarketresearch.com/request-sample/cancer-monoclonal-antibodies-market
With a share of over 39.5%, the market was ruled by humanized segment in 2021 on the basis of type. The mouse related epitope or immunogenic structures are replaced by humanized monoclonal antibodies. The humanization of mouse monoclonal antibodies is implemented widely, which has contributed to the market's expansion. This is because mouse monoclonal antibodies are inexpensive, readily available, and produced quickly. Additionally, humanized monoclonal antibodies make up 50% of recently approved mAbs.
On the basis of application, blood cancer segment in 2021 was the biggest market, with a share of 23.3%. There has been an enormous rise in the need for treatment methods for hematological disorders. This has propelled the pharmaceutical industry to create cutting-edge drugs like cancer monoclonal antibodies.
In the year 2021, the hospital segment held a considerable position in the market, with a share of 39.7% by end-user. The increasing incidence of cancer and the increase in patient hospitalizations are two factors that can be linked to the largest share of hospital segment. Additionally, patient preference is influenced by the availability of cutting-edge treatment methods in hospitals. Furthermore, the demand for products in hospitals is driven by trained professionals providing specialty treatments.
North America in 2021 contributed for highest market share of nearly 37.5%. Strategic actions largely influence the growth of the market. For example, AbbVie and I-Mab formed a strategic alliance to work on the development and research of the monoclonal antibody drug lemzoparlimab, also known as TJC4, which is used to treat a variety of cancers.
Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.
https://www.strategicmarketresearch.com/pre-order-enquiry/cancer-monoclonal-antibodies-market
Cancer Monoclonal Antibodies Market Report Coverage
| Report Attribute | Details |
| Forecast Period | 2021 - 2030 |
| The market size value in 2021 | USD 51.88 Billion |
| The revenue forecast in 2030 | USD 108.47 Billion |
| Growth rate | CAGR of approximately 8.54% |
| The base year for estimation | 2021 |
| Unit | USD Billion, CAGR (2021 - 2030) |
| Segmentation | By Solutions, By Deployment, By Region |
| By Medication Type | Rituximab (Rituxan), Bevacizumab (Avastin), Cetuximab (Erbitux), Panitumumab (Vectibix), Trastuzumab (Herceptin), and Others |
| By End-User | Hospitals and Clinics, Research Laboratories, Others |
| By Region | Asia Pacific, North America, Europe, LAMEA |
| Country Scope | U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. |
| Company Usability Profiles | Bristol Myers Squibb Company, Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche AG, Genmab AS, Amgen Inc., GlaxoSmithKline PLC, Eli Lilly and Company, Seattle Genetics Inc., and Spectrum Pharmaceuticals Inc., among others, hold the substantial market share in the market studied. |
Key players in Cancer Monoclonal Antibodies Market:
- Amgen Inc.
- Eli Lilly and Company
- Seattle Genetics Inc.
- Johnson & Johnson
- Novartis AG
- Genmab AS
- Spectrum Pharmaceuticals Inc.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Bristol Myers Squibb Company
To read the summary of the report, visit the website at
https://www.strategicmarketresearch.com/market-report/cancer-monoclonal-antibodies-market
Recent Developments
- The FDA has granted approval to the PD1 inhibitor Libtayo (cemiplimab-rwlc) in combined application with platinum-based chemotherapy for the first line treatment of adult cancer patients with enhanced non-small cell lung cancer (NSCLC), according to Regeneron Pharmaceuticals, Inc.
- Sairopa B.V. and Exelixis, Inc. announced that the companies had signed an exclusive clinical innovation and option alliance for ADU-1805, a monoclonal antibody that targets SIRP.
- At the 37th Pre-Conference Programs of the Society for cancer immunotherapy and Annual Meeting, Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies for cancer treatment, announced the presentation of two preclinical data abstracts centered on its natural killer cell pipeline and proprietary manufacturing technology.
Related Reports
Global Cancer Profiling Market Report
The Cancer Profiling Market report by SMR gives an insight into its driving factors, challenges, opportunities, etc. The Cancer Profiling Market in 2021 was USD 9.59 Billion and will be USD 26.31 Billion in 2030 at an 11.87% CAGR. The rising cases of cancer and the increase in microbiome effects are the factors accelerating its growth rate. Important companies in this market are Agendia, Perthera, Roche Diagnostics, Caris Life Sciences, etc.
Global Colonoscopy Devices Market Report
SMR's Colonoscopy Devices Market Report provides insights into its growth factors, restraints, and opportunities. The Colonoscopy Devices Market in 2021 was USD 1.37 Billion and will be worth USD 2.14 Billion with a 5.1% CAGR. Factors like the increasing rate of colorectal cancer and growing preference for minimally invasive procedures are expanding the market growth. Businesses in this market are Medtronic, HOYA Group, Boston Scientific, Fujifilm Holdings, Getinge Group, etc.
Global Microneedle Drug Delivery Systems Market Report
The Microneedle Drug Delivery Systems Market Report analyses its growth factors, challenges, restraints, etc. The Microneedle Drug Delivery Systems Market in 2021 was worth USD 5.71 billion and will reach USD 10.14 billion by 2030, with a 6.5% CAGR. Factors accelerating the growth rate are increasing incidence of obesity, Increased R&D, and growing investment in healthcare facilities. Key Companies in this market are Raphas Co. Ltd., Endoderma Ltd., Becton, Dickinson and Company, Nanopass Technologies Ltd., etc.
Global Veterinary Pain Management Market Report
The Veterinary Pain Management Market Report by SMR outlines its opportunities, challenges, restraints, etc. The Veterinary Pain Management Market in 2021 was USD 1.44 Billion and will be USD 2.92 Billion by 2030, representing an 8.12% CAGR. Key factors driving the market are increased adoption of diagnostic tools, innovation in diagnosis and vaccines, growing pet ownership, and increasing pet diseases. Market Players operating in this industry include Bayer Ag, Vibrac, Zoetics, Ceva, Norbrook, etc.
Global Antibody Drug Conjugates Market Report
SMR's Antibody Drugs Conjugates Market Report provides insights into its growth factors, challenges, opportunities, restraints, etc. The Antibody Drugs Conjugates Market's worth in 2021 was USD 4.00 Billion, and by 2030 it will be USD 13.13 Billion with a 14.12% CAGR. Growing cases of cancer and increased demand for antibody based cancer therapies are expediting the growth rate. Prominent organizations in this market are AstraZeneca, Seagen, Inc., ADC Therapeutics, Daiichi Sankyo Company Ltd., Pfizer, inc., etc.
.
About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.
Contact Us:
Strategic Market Research LLP.
Sunil Kumar
India: +91-8260836500
Email: info@strategicmarketresearch.com
Web: https://www.strategicmarketresearch.com
Blog: https://www.strategicmarketresearch.com/blog
Blog: https://www.strategicmarketresearch.com/blogs/metaverse-statistics
Press Release: https://www.strategicmarketresearch.com/press-releases
Connect Us:
LinkedIn: https://www.linkedin.com/company/strategic-market-research/
Twitter: https://twitter.com/smrstrategic
Facebook: https://www.facebook.com/StrategicMarketResearch
Instagram: https://www.instagram.com/strategicmarketresearchsmr/
